HHS announces major workforce cuts and reorganisation
The US Department of Health and Human Services (HHS) will cut 10,000 full-time employees and restructure its divisions as part…
All articles by Jenna Philpott
Jenna Philpott
Jenna Philpott is a news and features reporter for Pharmaceutical Technology. Jenna holds a BSc in Biochemistry and has interests in rare diseases, gene therapies, and oncology. Contact Jenna
-
-
GSK and UK researchers plan to study Shingrix and dementia risk reduction link
GSK is collaborating with the UK Dementia Research Institute (UK DRI) and Health Data Research UK (HDR UK) to investigate…
-
Investigating key strategies for optimising clinical trial supply chains in 2025
As the clinical trial landscape evolves with a growing demand for efficiency, flexibility, and innovation in 2025, experts will gather…
-
The trillion-dollar opportunity in women’s health
Closing the gap in health interventions between men and women could add $1tn to the global gross domestic product (GDP)…
-
Asceneuron halts Alzheimer’s trial adding to tau-targeting setbacks
After Eli Lilly and Biogen’s setbacks in developing O-GlaNAcase (OGA) inhibitors for Alzheimer’s disease, Asceneuron has now halted its own…
-
FDA removes clinical hold on Entrada’s Duchenne therapy
Entrada Therapeutics can plough on with the development of its Duchenne muscular dystrophy (DMD) therapy, ENTR-601-44, now that the US…
-
Struggling bluebird bio to go private for less than $30m
Bluebird bio will be acquired by investment firms Carlyle and SK Capital Partners, marking the end to its turbulent time…
-
Genentech eyes lupus market for Gazyva with positive Phase III data readout
Roche’s subsidiary Genentech has shared positive Phase III data with the US Food and Drug Administration (FDA) as the company…
-
Italian charity seeks EMA approval for rescued gene therapy
Italian research charity Telethon Foundation is one step closer to getting a gene therapy to treat rare disease Wiskott-Aldrich syndrome…
-
NHS England to offer Casgevy for sickle cell disease patients
The CRISPR-based gene therapy Casgevy (exagamglogene autotemcel) has been made available to patients with sickle cell disease in England, following…
